tirzepatide december 19 FDA Announces End To Compounded By March 19, 2025 US judge sides with FDA's

Several factors contribute to these elevated costs: Patent protection Most GLP-1 medications are still under patent, preventing generic competition Manufacturing complexity These are biologic medications that require specialized production processes Research and development costs Pharmaceutical companies invest heavily in clinical trials and regulatory approval Market positioning These medications are often priced as premium treatments Without insurance coverage, patients face the full retail price, which can make these medications financially inaccessible for many people who need them

If your goal is rapid, dramatic weight loss, one month will disappoint

Unlike older weight loss medications, tirzepatide's dual action enhances both appetite suppression and insulin regulation

But the medication may not be safe for certain people

We know that its not poison

For example, Novos $200M deal for Septernas triple agonist (mentioned) and Lillys $17B capex spree are part of that sum